NuCana Stock Soars 151% on Upbeat Efficacy Data From …
WEB5 days ago · NCNA. Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage study of its investigational candidate, NUC-7738, in combination ...
NuCana Presents Encouraging Data on NUC-7738 in Combination …
WEBSep 14, 2024 · NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
NuCana's Encouraging Data From Resistant Melanoma Treatment …
WEB6 days ago · NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD ...
NuCana plc (NCNA) Latest Stock News & Headlines - Yahoo …
WEBGet the latest NuCana plc (NCNA) stock news and headlines to help you in your trading and investing decisions.
NuCana's Encouraging Data From Resistant Melanoma Treatment …
WEB6 days ago · On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda ...
NuCana Presents Encouraging Data on NUC-7738 in
WEBSep 14, 2024 · NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently ...
NuCana plc (NCNA) Stock Price, News, Quote & History - Yahoo Finance
WEBFind the latest NuCana plc (NCNA) stock quote, history, news and other vital information to help you with your stock trading and investing.
News Releases | Investor Relations - NuCana plc
WEBMay 21, 2024 · NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
NuCana ADRs Nearly Double on Positive Data From
WEB6 days ago · NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98 ...
NuCana plc - ProTide technology to transform some of the most …
WEBWe apply our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. Learn more.
Skip to content